Author Archives: Charles Moore

St. Paul, Minnesota-based RespirTech, specialists in the design and manufacture of Airway Clearance Therapy (ACT) vest devices for persons with lung disorders, recently announced the discovery of a novel way to remotely monitor the treatment of cystic fibrosis (CF) patients. Work leading to the innovations was part…

Huge strides have been made in the treatment and management of cystic fibrosis (CF) in the past several decades. According to the U.S. National Institutes of Health (NIH), in 1962 the predicted median survival for cystic fibrosis patients was about 10 years, with few surviving into their teenage years. By the…

Austin, Texas-based International Biophysics Corporation, maker of AffloVest — a completely self-contained, battery operated, portable high-frequency chest wall oscillation (HFCWO) device for bringing critical therapy to people struggling with cystic fibrosis (CF), bronchiectasis, and other respiratory diseases — is joining several major U.S.

CysticLife.org, the largest patient-led social network for the cystic fibrosis (CF) community with more than 8,600 members, has partnered with researchers at the Mayo Clinic to conduct what it says will be the world’s largest CF exercise study. A report by rare disease information…

Ian Ross Pettigrew, the Hamilton, Ontario-based photographer and the creator of the Salty Girls photo project and book of the same name, is carrying on with the next stage of his project: capturing images of people living with cystic fibrosis (CF). Salty Kids will containing a gallery of images of children with…

Nivalis Therapeutics, Inc., a Boulder, Colorado-based clinical stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The purpose of this double-blind, randomized, placebo-controlled, parallel group study…

Cambridge, Massachusetts based Vertex Pharmaceuticals Incorporated reports that the European Commission (EC) has approved expansion of the indication for its cystic fibrosis drug KALYDECO (ivacaftor), which now includes children aged two to five with cystic fibrosis (CF) and who have one of nine gating mutations in the cystic…

Encouraging results of a study presented by the Katholieke Universiteit (KU) Leuven Laboratory for Molecular Virology and Gene Therapy at Leuven, Belgium indicate that improved gene therapy treatment can cure mice with cystic fibrosis (CF). The researchers note that cell cultures from CF patients also respond well to the…

Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics have announced that they will collaborate on drug research and development using CRISPR’s proprietary gene editing technology CRISPR-Cas9 to discover novel, potential treatments that address the underlying genetic causes of diseases such as cystic fibrosis (CF). The collaboration between Vertex and CRISPR will evaluate the use…

Persons with Cystic Fibrosis (CF) between ages 11 and 25 who think they can help inspire and engage other young people living with CF are being invited to check out a new program from the U.K.’s Cystic Fibrosis Trust. The Trust is reaching out to young people living with CF…